Nanox is reporting steady revenue for the first quarter of the 2025 fiscal year, which ended on March 31.
The company generated $2.8 million in revenue in the first quarter of 2025, compared with $2.6 million in the first quarter of 2024, according to Nanox's financial report. It also reported a net loss of $13.2 million, compared with a net loss of $12.2 million for the comparable period.
Among the company's highlights for the quarter are receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Nanox.ARC X multi-source digital tomosynthesis system and signing multiple commercial agreements to market the Nanox.ARC and the Nanox.AI products.
